THE EFFECT OF
SYMPATHOMIMETIC AMINES ON
RADIATION-INDUCED TOLERANCE TO
PENTOBARBITAL IN THE RAT

ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE
Defense Atomic Support Agency
Bethesda, Maryland

Distribution of this document is unlimited
All aspects of investigative programs involving the use of laboratory animals sponsored by DOD components are conducted according to the principles enunciated in the "Guide for Laboratory Animal Facilities and Care", prepared by the National Academy of Sciences - National Research Council.
THE EFFECT OF SYMPATHOMIMETIC AMINES ON RADIATION-INDUCED TOLERANCE TO PENTOBARBITAL IN THE RAT

D. J. MILETICH
S. L. BRADLEY
T. A. STRIKE

R. E. GEORGE
Commander, MSC, USN
Chairman
Radiation Biology Department

HUGH B. MITCHELL
Colonel, USAF, MC
Director

ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE
Defense Atomic Support Agency
Bethesda, Maryland

Distribution of this document is unlimited
ACKNOWLEDGMENT

The authors express their appreciation to R. H. Crutcher for his technical assistance during the course of this study.
TABLE OF CONTENTS

Foreword (Nontechnical summary) ........................................... iii
Abstract ................................................................. v
I. Introduction .......................................................... 1
II. Procedure ........................................................... 1
III. Results ............................................................. 4
IV. Discussion .......................................................... 5
References ............................................................. 7

LIST OF FIGURES

Figure 1. X-ray exposure array for rats ............................... 2
Figure 2. Setup for infusion of rats .................................. 3

TABLE

Table I. The Effects of X Ray, Amphetamine and Reserpine Administration on Pentobarbital Acute Toxicity in the Rat ................................. 4
FOREWORD
(Nontechnical summary)

Low doses of radiation are known to increase the normal background electrical activity of the nervous system of animals. This intensified activity generally results in an increased release of a chemical substance (neurotransmitter) from the nerve. Mice receiving sublethal doses of radiation have been shown to respond less to pentobarbital than unirradiated control animals. This increased tolerance of mice to pentobarbital appears related to the increased release of neurotransmitter. The present study examines this relationship in rats using x radiation and drugs known to effect the release of neurotransmitter.

Male rats were given 250-, 500-, or 1000-rad midline tissue doses of 300 kVp x rays. Twenty-four hours after irradiation, the rats of all groups were infused with sodium pentobarbital at a constant rate until respiration ceased. The amount of pentobarbital needed to reach this end point was determined and the mean value of each group was statistically compared with that of an unirradiated control group. Reserpine treatment and/or amphetamine treatment were given to other groups of irradiated and unirradiated rats and pentobarbital toxicity similarly measured in these animals.

Increased tolerance (amount of drug necessary to stop respiration) to sodium pentobarbital was observed in the rats after 500- or 1000-rad doses, but not in the rats receiving 250 rads. A similar increased tolerance was seen in amphetamine-treated unirradiated rats. Animals receiving reserpine alone or in combination with amphetamine and/or radiation, had essentially the same pentobarbital tolerance as
control animals. Furthermore, amphetamine administration eliminated the increased tolerance ordinarily seen 24 hours after 1000 rads of x rays.

The results indicate that the neurotransmitter norepinephrine plays some role in the increased pentobarbital tolerance of rats observed after irradiation.
ABSTRACT

Male Sprague-Dawley rats were given 250-, 500-, or 1000-rad midline tissue doses of 300 kVp x rays. Twenty-four hours postirradiation the acute toxicity of sodium pentobarbital was determined in these animals. Rats receiving 500 and 1000 rads demonstrated an increased tolerance to sodium pentobarbital, but no change in toxicity was observed in animals given 250 rads. This radiation-induced increase in pentobarbital tolerance was similar in degree to that observed in unirradiated rats treated with amphetamine, a known barbiturate antagonist. However, when rats received amphetamine as well as 1000 rads of x rays no increased tolerance to sodium pentobarbital was observed. Four days of reserpine treatment prior to irradiation also abolished the radiation-induced increase in sodium pentobarbital tolerance.

These results suggest that increased central norepinephrine levels are responsible for the radiation-induced increase in tolerance to pentobarbital.
Sublethal doses of radiation have been shown to increase the electrical background activity of the central nervous system (CNS). Barnes reported that 102 R of x rays enhanced pentobarbital tolerance in mice. He suggested that this radiation-induced increase in tolerance to pentobarbital is due to facilitated CNS electrical activity antagonizing barbiturate depression.

Under normal physiologic conditions facilitated CNS electrical transmissions would result in an increased release of central neurotransmitter. If radiation increases tolerance to pentobarbital by facilitating electrical activity, then drugs which increase the release rate of or deplete stored quantities of central neurotransmitter should modify radiation-induced changes in pentobarbital toxicity. The ability of irradiated rats to tolerate pentobarbital was measured after treatment with amphetamine and/or reserpine to test this hypothesis.

II. PROCEDURE

Male Sprague-Dawley rats* (250-300 grams) were housed one per cage in an environmental controlled room and acclimated for a minimum of 1 week.

Rats were bilaterally irradiated using an x-ray machine and the following exposure factors: 300 kVp, 20 mA, HVL 1.5 mm Cu, and source to animal center line distance of 50 cm. The animals were placed in rectangular Plexiglas boxes and two rats were irradiated at the same time (Figure 1). Depth-dose measurements made in cylindrical Plexiglas rat phantoms using miniature tissue-equivalent ionization chambers showed that the maximum to minimum dose ratio through the phantom

* Environmental Control Co., Washington, D. C.
was 1.09 indicating that the exposures were Class A. The dose rate at the midline of the phantom was 129 rads per minute. Groups of rats received midline tissue doses of 250, 500, or 1000 rads.

Sodium pentobarbital acute toxicity was determined 24 hours after the animals were irradiated. Control, fasted control, and irradiated animals were lightly anesthetized with ether and the tail vein catheterized using a 23-gauge needle attached to polyethylene tubing (i.d. 0.011", o.d. 0.024"). The rats were then confined in Plexiglas cylinders and allowed to recover from the anesthesia. Pentobarbital was infused via the polyethylene tubing at a constant rate of $2.95 \text{ mg min}^{-1}$ (0.116 ml of solution min$^{-1}$) using an infusion pump. The assembled apparatus is shown in Figure 2. The end point of acute toxicity for pentobarbital in the animal was the cessation of respiration. The amount of pentobarbital required to achieve this end point was calculated as milligrams per kilogram of body weight.
The effect of amphetamine sulfate on pentobarbital toxicity was determined in irradiated (24 hours after 1000 rads) and in unirradiated rats. Amphetamine (8 mg kg$^{-1}$) was administered intraperitoneally 1/2 hour prior to pentobarbital infusion (a time sufficient to insure the onset of drug activity as indicated by restlessness, agitation, and increased motor activity of the animals). The effect of preirradiation reserpine treatment (0.1 mg kg$^{-1}$ day$^{-1}$ intramuscularly for 4 days) on pentobarbital acute toxicity was tested in irradiated (24 hours after 1000 rads) and in unirradiated rats. The same regimen of reserpine treatment was tested in conjunction with amphetamine given 1/2 hour prior to pentobarbital infusion in irradiated (24 hours after 1000 rads) and in unirradiated rats.

Differences between the mean values of the test groups were evaluated for statistical significance using Student's "t" test.
III. RESULTS

Table I summarizes the results. Rats demonstrated an increased pentobarbital tolerance 24 hours after receiving 500 and 1000 rads, but not after 250 rads. Fasting unirradiated rats for 48 hours had no effect on pentobarbital tolerance.

Unirradiated, amphetamine-treated rats demonstrated an increased ability to tolerate pentobarbital. When amphetamine was administered to animals 24 hours after a 1000-rad dose, however, a decrease in pentobarbital tolerance was observed; this decrease was not significant at the 0.05 level of probability.

Four days of reserpine treatment abolished the increased tolerance to pentobarbital in unirradiated amphetamine-treated rats as well as in irradiated rats.

Table I. The Effects of X Ray, Amphetamine and Reserpine Administration on Pentobarbital Acute Toxicity in the Rat

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Number of rats</th>
<th>Toxic dose of pentobarbital mg kg⁻¹ ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>29</td>
<td>87.2 ± 5.5</td>
</tr>
<tr>
<td>Control, fasted 48 h</td>
<td>12</td>
<td>85.7 ± 5.2</td>
</tr>
<tr>
<td>Irradiated (24 h after 250 rads)</td>
<td>15</td>
<td>85.6 ± 4.8</td>
</tr>
<tr>
<td>Irradiated (24 h after 500 rads)</td>
<td>12</td>
<td>*107.6 ± 5.4</td>
</tr>
<tr>
<td>Irradiated (24 h after 1000 rads)</td>
<td>12</td>
<td>*106.3 ± 3.5</td>
</tr>
<tr>
<td>Amphetamine treated</td>
<td>21</td>
<td>*105.7 ± 4.8</td>
</tr>
<tr>
<td>Amphetamine treated (24 h after 1000 rads)</td>
<td>18</td>
<td>76.5 ± 5.0</td>
</tr>
<tr>
<td>Reserpine treated</td>
<td>7</td>
<td>85.9 ± 7.1</td>
</tr>
<tr>
<td>Reserpine and Amphetamine treated</td>
<td>9</td>
<td>91.2 ± 4.8</td>
</tr>
<tr>
<td>Reserpine treated (24 h after 1000 rads)</td>
<td>10</td>
<td>91.1 ± 5.9</td>
</tr>
<tr>
<td>Reserpine and Amphetamine treated (24 h after 1000 rads)</td>
<td>11</td>
<td>84.7 ± 2.9</td>
</tr>
</tbody>
</table>

*p <0.05 (treatment group compared with control group)
IV. DISCUSSION

Five hundred- and 1000-rad whole-body doses of x rays were antagonistic to the depressant action of pentobarbital on the CNS of the rat; however, no such effect resulted from a dose of 250 rads. The increased ability to tolerate pentobarbital was not due to inappetence of the animals since unirradiated rats fasted for 48 hours did not show any change in pentobarbital tolerance as compared to fed control animals. The increased central neuronal activity suggested by the data from this study appears to confirm the reported increase in CNS electrical activity following exposure to radiation.

In situations of stress, the immediate physiologic response of the animal is attempted restoration of homeostasis. A large facilitatory input from the peripheral organs is transmitted to the reticular activating system which in turn increases the electrical activity of nearly all parts of the CNS to accomplish this restoration. Increased bioelectrical activity would result in an increased release of central neurotransmitters, particularly in the important respiratory and vasomotor centers located in the midbrain. Chief of these neurotransmitters is norepinephrine which is normally found in high concentrations throughout this region of the CNS.

Reserpine and amphetamine were studied in various combinations with pentobarbital and irradiation. Both drugs act centrally by increasing the release of norepinephrine. Amphetamine's well-known antagonism to pentobarbital was observed as a decreased pentobarbital toxicity in unirradiated animals. This decreased pentobarbital toxicity appeared similar to that observed following irradiation. However, irradiated rats treated with amphetamine appeared to have a decreased tolerance
to pentobarbital, 24 hours postexposure (1000 rads), as compared to control animals (the decrease was not statistically significant in this experiment). From these data, it appears that when x radiation and amphetamine treatment are combined the ability of each to counteract CNS pentobarbital depression is lost. It is difficult to explain why the combination of amphetamine and irradiation does not increase pentobarbital tolerance when each used singly does. It is possible that the combination of amphetamine and irradiation exceeds a maximum limit after which central neuronal facilitation is reflectively inhibited or intoxicated.

Reserpine is an intraneuronal depletor of norepinephrine. Reserpinization abolished the increased tolerance of irradiated animals to pentobarbital. This observation further implicates central norepinephrine in the decreased pentobarbital toxicity caused by x irradiation. Similar effects of reserpinization on pentobarbital toxicity were observed in amphetamine-treated rats.

The findings of this study indicate that 500 and 1000 rads of x rays increased the rat's ability to tolerate pentobarbital. This increased tolerance appeared similar to that obtained using amphetamine, a known pentobarbital antagonist. Two hundred and fifty rads of radiation failed to increase pentobarbital tolerance indicating a threshold dose of radiation is necessary to elicit this response. The radiation-induced increase in pentobarbital tolerance is abolished by reserpine treatment or by combining amphetamine treatment with irradiation.
REFERENCES


# DISTRIBUTION LIST

**AIR FORCE**

Executive Officer, Director of Professional Services, Office of the Surgeon General, Hq. USAF (AFMSPA) T-8, Washington, D. C. 20333 (1)
Headquarters, U. S. Air Force (AFMSPAB), Washington, D. C. 20333 (1)
Chief, Weapons and Weapons Effects Division, Hq. RTD (RTTW), Bolling AFB, Washington, D. C. 20332 (1)
Office of the Command Surgeon (ADCg), Hq. ADC, USAF, Ent AFB, Colorado 80912 (1)
Commander, 6571st Aeromedical Research Laboratory, Holloman AFB, New Mexico 88330 (2)
Air Force Weapons Laboratory, ATTN: WLIL (1), ATTN: WLRB-2 (1), Kirtland AFB, New Mexico 87117 (2)
Chief, Nuclear Medicine Department, P. O. Box 5088, USAF Hospital Wright-Patterson, Wright-Patterson AFB, Ohio 45433 (1)

**USAFSAM (SMBR), ATTN: Chief, Radiobiology Branch, Brooks AFB, Texas 78235 (1)**

**ARMY**

The Surgeon General, U. S. Department of the Army, Washington, D. C. 20315 (1)
USACDC CSSG, Doctrine Division, Fort Lee, Virginia 23801 (1)
Commanding Officer, USACDC CBR Agency, Fort McClellan, Alabama 36201 (1)
Commanding Officer, U. S. Army Combat Developments Command, Institute of Nuclear Studies, Fort Bliss, Texas 79916 (1)
CG, USCONARC, ATTN: ATUTR-TNC (NBC), Fort Monroe, Virginia 23351 (1)
Commanding Officer, Harry Diamond Laboratories, ATTN: Nuclear Vulnerability Branch, Washington, D. C. 20438 (1)
Commanding Officer, U. S. Army Medical Research Laboratory, Fort Knox, Kentucky 40121 (1)
Commanding Officer, USA Nuclear Medical Research Detachment, Europe, APO New York, New York 09180 (2)
Chief of Research and Development, ATTN: Nuclear, Chemical and Biological Division, U. S. Department of the Army, Washington, D. C. 20310 (1)

Army Research Office, ATTN: Chief, Scientific Analysis Branch, Life Sciences Division, 3045 Columbia Pike, Arlington, Virginia 22204 (1)
Division of Nuclear Medicine, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, D. C. 20012 (5)
Commanding Officer, U. S. Army Environmental Hygiene Agency, ATTN: USAEHA-RP, Edgewood Arsenal, Maryland 21010 (1)
Commandant, U. S. Army Medical Field Service School, ATTN: MEDEW - ZNW, Fort Sam Houston, Texas 78234 (1)

**NAVY**

Chief, Bureau of Medicine and Surgery, U. S. Navy Department, Washington, D. C. 20390 (1)
Commanding Officer, Naval Aerospace Medical Institute, Naval Aviation Medical Center, ATTN: Director of Research, Pensacola, Florida 32512 (3)
Commanding Officer, Nuclear Weapons Training Center, Atlantic, Nuclear Warfare Department, Norfolk, Virginia 23511 (1)
Commanding Officer, Nuclear Weapons Training Center, Pacific, U. S. Naval Air Station, North Island, San Diego, California 92135 (1)
Director, Biological Sciences Division, Office of Naval Research, Washington, D. C. 20360 (1)
Commanding Officer, U. S. Naval Hospital, ATTN: Director, REEL, National Naval Medical Center, Bethesda, Maryland 20014 (1)
Head, Animal Behavioral Sciences Branch, Naval Aerospace Medical Institute, Naval Aerospace Medical Center, Pensacola, Florida 32512, ATTN: Dr. John S. Thach, Jr. (1)
D.O.D.

Director, Defense Atomic Support Agency, Washington, D. C. 20305 (1)
Director, Defense Atomic Support Agency, ATTN: DDST, Washington, D. C. 20305 (1)
Director, Defense Atomic Support Agency, ATTN: Chief, Medical Directorate, Washington, D. C. 20305 (4)
Director, Defense Atomic Support Agency, ATTN: Chief, Radiation Directorate, Washington, D. C. 20305 (1)
Commander, Field Command, Defense Atomic Support Agency, ATTN: FC Technical Library, Sandia Base, Albuquerque, New Mexico 87115 (1)
Commander, Headquarters Field Command, Defense Atomic Support Agency, ATTN: FCTG8, Sandia Base, Albuquerque, New Mexico 87115 (2)
Director, Armed Forces Institute of Pathology, Washington, D. C. 20305 (1)
Administrator, Defense Documentation Center, Cameron Station, Bldg. 5, Alexandria, Virginia 22314 (20)

OTHER GOVERNMENT

U. S. Atomic Energy Commission, Headquarters Library, Reports Section, Mail Station G-17, Washington, D. C. 20545 (1)
U. S. Atomic Energy Commission, Division of Biology and Medicine, Washington, D. C. 20545 (1)
U. S. Atomic Energy Commission, Bethesda Technical Library, 7920 Norfolk Avenue, Bethesda, Maryland 20014 (1)
National Aeronautics and Space Administration, ATTN: Lt. Col. Charles M. Barnes, USAF, DB-3, MSC, Houston, Texas 77058 (1)
National Bureau of Standards, ATTN: Chief, Radiation Physics Division, Washington, D. C. 20234 (1)
U. S. Public Health Service, Deputy Chief, Division of Radiological Health, Washington, D. C. 20201 (1)
U. S. Public Health Service, Radiological Health Laboratory, ATTN: Library, 1901 Chapman Avenue, Rockville, Maryland 20852 (1)
U. S. Public Health Service, Northeastern Radiological Health Laboratory, 109 Holton Street, Winchester, Massachusetts 01890 (1)
U. S. Public Health Service, Southwestern Radiological Health Laboratory, P. O. Box 684, Las Vegas, Nevada 89101 (1)
U. S. Public Health Service, National Center for Radiological Health, Information Office, Room 3, Twinbrook Laboratory, 1901 Chapman Avenue, Rockville, Maryland 20852 (1)

OTHER

Argonne National Laboratory, Library Services Department, Report Section Bldg. 203, RM-CE-125, 9700 South Cass Avenue, Argonne, Illinois 60439 (1)
Dr. Donald G. Baker, Radiobiology Department, Zellerbach Saroni Tumor Institute, 1600 Divisadero Street, San Francisco, California 94115 (1)
Brookhaven National Laboratory, Information Division, ATTN: Research Library, Upton, Long Island, New York 11973 (2)
Dr. J. S. Burkle, Director of Nuclear Medicine, York Hospital, York, Pennsylvania 17403 (1)
S. C. Bushong, Department of Radiology, Baylor University College of Medicine, Houston, Texas 77024 (1)
University of California, Lawrence Radiation Laboratory, Library, Bldg. 50, Room 134, Berkeley, Calif. 94720 (1)
Director, Radiobiology Laboratory, University of California, Davis, California 95616 (1)
University of California, Lawrence Radiation Laboratory, Technical Information Division Library L-3, P. O. Box 808, Livermore, California 94551 (2)
University of California, Laboratory of Nuclear Medicine and Radiobiology, Library, 900 Veteran Avenue, Los Angeles, California 90024 (1)
Dr. C. Jelleff Carr, Director, Life Sciences Research Office, Federation of American Societies for Experimental Biology, 9650 Rockville Pike, Bethesda, Maryland 20014 (1)
Director, Collaborative Radiological Health Laboratory, Colorado State University, Fort Collins, Colorado 80521 (1)
Dr. L. W. Davis, Radiology Department, University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pa. 19104 (1)
Professor Merrill Eisenbud, New York University, Tuxedo, New York 10987 (1)
Dr. T. C. Evans, Radiation Research Laboratory, College of Medicine, University of Iowa, Iowa City, Iowa 52240 (1)
Dr. Arnold Feldman, Institute of Radiology, School of Medicine, Washington University, 510 South Kingshighway, St. Louis, Missouri 63110 (1)
Mr. Orin Gelderloos, Department of Biological Sciences, Northwestern University, Evanston, Illinois 60201 (1)
General Dynamics/Fort Worth, ATTN: Librarian, P. O. Box 748, Fort Worth, Texas 76101 (1)
Gulf General Atomic Incorporated, ATTN: Library, P. O. Box 608, San Diego, California 92112 (1)
Hazleton Nuclear Science Corporation, ATTN: Library, 4062 Fabian Way, Palo Alto, California 94303 (1)
IIT Research Institute, ATTN: Document Library, 10 West 35th Street, Chicago, Illinois 60616 (1)
Johns Hopkins University, Applied Physics Laboratory, ATTN: Document Library, 8621 Georgia Avenue, Silver Spring, Maryland 20910 (1)

Dr. R. F. Kallman, Department of Radiology, Stanford University, Palo Alto, California 94305 (1)

Dr. L. S. Kelly, Donner Laboratory, University of California at Berkeley, Berkeley, California 94720 (1)

Los Alamos Scientific Laboratory, ATTN: Report Librarian, P. O. Box 1663, Los Alamos, New Mexico 87544 (1)

Director, Nuclear Science Center, Louisiana State University, Baton Rouge, Louisiana 70803 (2)

Lovelace Foundation for Medical Education & Research, Document Library, 5200 Gibson Boulevard, S. E., Albuquerque, New Mexico 87108 (1)

Dr. Ross A. McFarland, Guggenheim Professor of Aerospace Health & Safety, Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115 (1)

Dr. J. I. Marcum, Rand Corporation, 1700 Main Street, Santa Monica; California 90401 (1)

Massachusetts Institute of Technology, M.I.T. Libraries, Technical Reports, Room 14 E-210, Cambridge, Massachusetts 02139 (1)

Dr. Charles W. Mays, Physics Group Leader, Radiobiology Division, University of Utah, Salt Lake City, Utah 84112 (1)

Dr. B. D. Newsom, Colony Oaks, Apt. 32, 18100 Nassau Bay Drive, Nassau Bay, Texas 77058 (1)

Ohio State University, Nuclear Reactor Laboratory, 1298 Kinnear Road, Columbus, Ohio 43212 (1)

Dr. Harvey M. Patt, Laboratory of Radiobiology, University of California, San Francisco Medical Center, San Francisco, California 94122 (1)

Purdue University, Nuclear Engineering Library, Lafayette, Indiana 47907 (1)

Dr. S. M. Reichard, Director, Division of Radiobiology, Medical College of Georgia, Augusta, Georgia 30902 (1)

University of Rochester, Atomic Energy Project Library, P. O. Box 287, Station 3, Rochester, New York 14620 (1)

Dr. H. H. Rossi, 630 West 168th Street, New York, New York 10032 (1)

Dr. Eugene L. Saenger, Director, Radioisotope Laboratory, Cincinnati General Hospital, Cincinnati, Ohio 45229 (1)

Sandia Corporation Library, P. O. Box 5800, Albuquerque, New Mexico 87115 (1)

Scientific Committee on the Effects of Atomic Radiation, ATTN: Library, United Nations Room 3267, United Nations Plaza, New York, New York 10017 (1)

Scope Publications, Franklin Station, P. O. Box 7407, Washington, D. C. 20004 (1)

University of Southern California, Nuclear Physics Laboratory, University Park, Los Angeles, California 90007 (1)

Dr. Arthur R. Tamplin, Biophysicist, Information Integration Group, University of California, Lawrence Radiation Laboratory, L-612, Livermore, California 94550 (1)

Radiation Biology Laboratory, Texas Engineering Experiment Station, Texas A. & M. University, College Station, Texas 77840 (2)

Texas Nuclear Corporation, ATTN: Director of Research, Box 9267 Allandale Station, Austin, Texas 78756 (1)

Western Reserve University, Department of Radiology, Division of Radiation Biology, Cleveland, Ohio 44106 (1)

Mr. Lionel Zamore, 601 Brightwater Court, Brooklyn, New York 11235 (1)

 FOREIGN

International Atomic Energy Agency, Kaerntnerring 11, Vienna I, 1010, Austria (1)

European Atomic Energy Community, C. E. F. A., Library, 51 rue Beillard, Brussels 4, Belgium (1)

Dr. L. G. Lajtha, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester, England (1)

Dr. L. F. Lamerton, Biophysics Department, Institute of Cancer Research, Surrey Branch, Belmont, Sutton, Surrey, England (1)

National Lending Library for Science and Technology, Boston Spa, Yorkshire, England (1)

Directorate of Medical and Health Services, FAF (Federal Armed Forces), Bonn, Ernkei1str. 27, West Germany (1)

Abteilung fur Strahlenbiologie im Institut fur Biophysik der Universitat Bonn, 53 Bonn-Venusberg, Annaberger Weg 15, Federal Republic of Germany (2)

Prof. Dr. H. Langendorff, Direktor des Radiologischen Instituts der Universität, 78 Freiburg im Breisgau, Albertstrasse 23, Germany (1)

Dr. Helmut Mitschrich, Akademie des Sanitaets-und Gesundheits, Weseus BW, Spezialstab ATV, 8 Muenchen Schwere-Reiterstr. 4, Germany (2)

Prof. Dr. F. Wachsmann, Gesellschaft fur Strahlenforschung m. b. H., 8042 Neuherberg bei Muenchen, Institut fur Strahlenbiologie und Strahlenschutz, Ingolstatter Landstrasse 1, Muenchen, Germany (1)

Dr. M. Feldman, Section of Cell Biology, The Weizmann Institute of Science, Rehovoth, Israel (1)

Dr. G. W. Barendsen, Radiobiological Institute TNO, Rijswijk, Netherlands (1)

Dr. L. M. van Putten, Radiobiological Institute TNO, 151 Lance Kleiweg, Rijswijk 2 H., Netherlands (1)

Puerto Rico Nuclear Center, ATTN: Reading Room, College Station, Mayaguez, Puerto Rico 00708 (2)

Dr. H. Cottier, Pathological Institut der Universität, Bern, Switzerland (1)
Male Sprague-Dawley rats were given 250-, 500-, or 1000-rad midline tissue doses of 300 kVp x rays. Twenty-four hours postirradiation the acute toxicity of sodium pentobarbital was determined in these animals. Rats receiving 500 and 1000 rads demonstrated an increased tolerance to sodium pentobarbital, but no change in toxicity was observed in animals given 250 rads. This radiation-induced increase in pentobarbital tolerance was similar in degree to that observed in unirradiated rats treated with amphetamine, a known barbiturate antagonist. However, when rats received amphetamine as well as 1000 rads of x rays no increased tolerance to sodium pentobarbital was observed. Four days of reserpine treatment prior to irradiation also abolished the radiation-induced increase in sodium pentobarbital tolerance. These results suggest that increased central norepinephrine levels are responsible for the radiation-induced increase in tolerance to pentobarbital.
### INSTRUCTIONS

1. **ORIGINATING ACTIVITY:** Enter the name and address of the contractor, subcontractor, grantee, Department of Defense activity or other organization (corporate author) issuing the report.

2a. **REPORT SECURITY CLASSIFICATION:** Enter the overall security classification of the report. Indicate whether "Restricted Data" is included. Marking is to be in accordance with appropriate security regulations.

2b. **GROUP:** Automatic downgrading is specified in DoD Directive 5200.10 and Armed Forces Industrial Manual. Enter the group number. Also, when applicable, show that optional link markings have been used for Group 3 and Group 4 as authorized.

3. **REPORT TITLE:** Enter the complete report title in all capital letters. Titles in all cases should be unclassified. If a meaningful title cannot be selected without classification, show title classification in all capitals immediately following the title.

4. **DESCRIPTIVE NOTES:** If appropriate, enter the type of report, e.g., interim, progress, summary, annual, or final. Give the inclusive dates when a specific reporting period is covered.

5. **AUTHOR(S):** Enter the name(s) of author(s) as shown on or in the report. Enter last name, first name, middle initial. If military, show rank and branch of service. The name of the principal author is an absolute minimum requirement.

6. **REPORT DATE:** Enter the date of the report as day, month, year, or month, year. If more than one date appears on the report, use date of publication.

7a. **TOTAL NUMBER OF PAGES:** The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.

7b. **NUMBER OF REFERENCES:** Enter the total number of references cited in the report.

8a. **CONTRACT OR GRANT NUMBER:** If appropriate, enter the applicable number of the contract or grant under which the report was written.

8b, 8c, & 8d. **PROJECT NUMBER:** Enter the appropriate military department identification, such as project number, subproject number, system numbers, task number, etc.

9a. **ORIGINATOR'S REPORT NUMBER(S):** Enter the official report number by which the document will be identified and controlled by the originating activity. This number must be unique to this report.

9b. **OTHER REPORT NUMBER(S):** If the report has been assigned any other report numbers (either by the originator or by the sponsor), also enter this number(s).

10. **AVAILABILITY/LIMITATION NOTICES:** Enter any limitations on further dissemination of the report, other than those imposed by security classification, using standard statements such as:

   (1) "Qualified requesters may obtain copies of this report from DDC."

   (2) "Foreign announcement and dissemination of this report by DDC is not authorized."

   (3) "U. S. Government agencies may obtain copies of this report directly from DDC. Other qualified DDC users shall request through"

   (4) "U. S. military agencies may obtain copies of this report directly from DDC. Other qualified users shall request through"

   (5) "All distribution of this report is controlled. Qualified DDC users shall request through"

   If the report has been furnished to the Office of Technical Services, Department of Commerce, for sale to the public, indicate this fact and enter the price, if known.

11. **SUPPLEMENTARY NOTES:** Use for additional explanatory notes.

12. **SPONSORING MILITARY ACTIVITY:** Enter the name of the departmental project office or laboratory sponsoring (paying for) the research and development. Include address.

13. **ABSTRACT:** Enter an abstract giving a brief and factual summary of the document indicative of the report, even though it may also appear elsewhere in the body of the technical report. If additional space is required, a continuation sheet shall be attached.

   It is highly desirable that the abstract of classified reports be unclassified. Each paragraph of the abstract shall end with an indication of the military security classification of the information in the paragraph, represented as (TS), (S), (C), or (U).

   There is no limitation on the length of the abstract. However, the suggested length is from 150 to 225 words.

14. **KEY WORDS:** Key words are technically meaningful terms or short phrases that characterize a report and may be used as index entries for cataloging the report. Key words must be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location, may be used as key words but will be followed by an indication of technical context. The assignment of links, rules, and weights is optional.